Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.
On June 26 and 27, the 24th annual meeting of China Association for Science and Technology (CAST) themed “Led by Innovation, Self-reliance-Building A New Engine of the Rise of Central China” jointly hosted by CAST and Hunan Provincial People’s Government was held in Changsha, Hunan. In the annual meeting, Sansure Biotech was awarded with the plaque of Enterprise Association of […]
Accompanied by the management from Office of Foreign Affairs Commission of CPC Hunan Provincial Committee, H.E. Allan Chintedza, the Ambassador of Malawi to China, and Oliver Kingstone Chimphambano, the Deputy Ambassador of Malawi to China, visited Sansure Biotech on June 23rd. Dr. Lizhong Dai, the Chairman of Sansure Biotech was also along with the visit. Ambassador Allan Chintedza visited the […]
On June 20, Jo Hawley, the British Consul General in Guangzhou, and Mr. Mike McCourt, Healthcare Director in China for the British Department of International Trade China, visited Sansure Biothech. They were accompanied by the management from Changsha High-Tech Development Zone, along with Dr. Lizhong Dai, the Chairman of Sansure. During the visit, they had an in-depth discussion on further […]
On June 7, the new generation of iPonatic full-automatic nucleic acid testing and analysis system of Sansure Biotech was certified by IVDR CE, which will better serve the construction of public health prevention and control system globally. CE certification is mandatory for product access to the EU market. From May 26, 2022, the EU comprehensively implemented in vitro diagnosis medical […]
On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million yuan B+ round of financing. This round of financing is led by Forestone Capital, followed by funds from Yinhe Yuanhui, Guojing Capital, Junci Investment, Qiandao Investment, Best, Brilliance Investment. As a strategic investor, Sansure Biotech followed the investment, and […]